Obstructive sleep apnoea as a risk factor for atherosclerosis - implication for preventive and personalised treatment

EPMA Journal

Volumn 2, Issue 1, 2011, Pages 39-47

  Tuleta, Izabela ^a   Pabst, Stefan ^a   Juergens, Uwe R ^a   Nickenig, Georg ^a   Skowasch, Dirk ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Atherosclerosis; CPAP; Intermittent hypoxia; Obstructive sleep apnoea; Personalised treatment; Predictive biomarkers

Indexed keywords

ASCORBIC ACID; BIOLOGICAL MARKER; BOSENTAN; C REACTIVE PROTEIN; CD40 LIGAND; ENDOTHELIN 1; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; L SELECTIN; LEUKOTRIENE B4; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ATHEROSCLEROSIS; BRAIN INFARCTION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GOLD STANDARD; HEART INFARCTION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 79955659324     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-011-0070-5     Document Type: Review

References (103)

1. Skowasch D, Boenner G, Nickenig G. Obstructive sleep apnea as a risk factor of atherosclerosis. Somnologie. 2009; 13: 215-20.
2. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005; 353: 999-1007.
3. Andrié R, Bauriedel G, Braun P, Höpp HW, Nickenig G, Skowasch D. Increased expression of C-reactive protein and tissue factor in acute coronary syndrome lesions. Atherosclerosis. 2009; 202: 135-43.
4. Podszus T, Seevers H, Mayer G, Baumann G. Positionspapier "Schlafmedizin in der Kardiologie". Kardiologe. 2009; 3: 9-15.
5. Caples SM, Garcia-Touchard A, Somers VK. Sleep-disordered breathing and cardiovascular risk. Sleep. 2007; 30: 291-304.
6. Lüthje L, Andreas S. Obstructive sleep apnea and coronary artery disease. Sleep Med Rev. 2008; 12: 19-31.
7. Lopez-Jimenez F, Kuniyoshi FHS, Gami A, Somers VK. Obstructive sleep apnea. Implications of cardiac and vascular disease. Chest. 2008; 133: 793-804.
8. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease. Circulation. 2008; 118: 1080-111.
9. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet. 2009; 373: 82-9310.
10. Basner RC. Continuous positive airway pressure for obstructive sleep apnea. N Engl J Med. 2007; 356: 1751-8.
11. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995; 96: 1897-904.
12. Phillips BG, Narkiewicz K, Pesek CA, Haynes WG, Dyken ME, Somers VK. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens. 1999; 17: 61-6.
13. Teramoto S, Kume H, Matsuse T, et al. Oxygen administration improves the serum level of nitric oxide metabolites in patients with obstructive sleep apnea syndrome. Sleep Med. 2003; 4: 403-7.
14. Kraiczi H, Caidahl K, Samuelsson A, Peker Y, Hedner J. Impairment of vascular endothelial function and left ventricular filling: association with the severity of apnea-induced hypoxemia during sleep. Chest. 2001; 119: 1085-91.
15. Lavie L, Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J. 2009; 33: 1467-84.
16. Duchna HW, Guilleminault C, Stoohs RA, et al. Obstructive sleep apnea syndrome: a cardiovascular risk factor? Z Kardiol. 2001; 90: 568-75.
17. Arias MA, Garcia-Rio F, Alonso-Fernandez A, Mediano O, Martínez I, Villamor J. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation. 2005; 112: 375-83.
18. Ohga E, Tomita T, Wada H, Yamamoto H, Nagase T, Ouchi Y. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol. 2003; 94: 179-84.
19. Zund G, Uezono S, Stahl GL, et al. Hypoxia enhances induction of endothelial ICAM-1: role for metabolic acidosis and proteasomes. Am J Physiol. 1997; 273: C1571-80.
20. Dyugoskava L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med. 2002; 165: 934-9.
21. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation. 2002; 105: 1462-4.
22. Svatikova A, Wolk R, Shamsuzzaman AS, Kara T, Olson EJ, Somers VK. Serum amyloid A in obstructive sleep apnea. Circulation. 2003; 108: 1451-4.
23. Larkin EK, Rosen CL, Kirchner HL, et al. Variation of C-reactive protein levels in adolescents: association with sleep-disordered breathing and sleep duration. Circulation. 2005; 111: 1978-84.
24. Guillemiault C, Kirisoglu C, Ohayon MM. C-reactive protein and sleep-disordered breathing. Sleep. 2004; 27: 1507-11.
25. Jelic S, Padeletti M, Kawut SM, et al. Inflammation, oxidative stress and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation. 2008; 117: 2270-8.
26. Ip MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med. 2004; 169: 348-53.
27. El Solh AA, Akkinnusi ME, Baddoura FH, Mankowski CR. Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med. 2007; 175: 1186-91.
28. Nieto FJ, Herrington DM, Redline S, Benjamin EJ, Robbins JA. Sleep apnea and marker of vascular endothelial function in a large community sample of older adults. Am J Crit Care Med. 2004; 169: 354-60.
29. von Känel R, Loredo JS, Ancoli-Israel S, Mills PJ, Natarajan L, Dimsdale JE. Association between polysomnographic measures of disrupted sleep and prothrombotic factors. Chest. 2007; 131: 733-9.
30. Phillips BG, Hisel TM, Kato M, et al. Recent weight gain in patients with newly diagnosed obstructive sleep apnea. J Hypertens. 1999; 17: 1297-300.
31. Chin K, Shimizu K, Nakamura T, et al. Changes in intraabdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous sleep apnea pressure therapy. Circulation. 1999; 100: 706-12.
32. Jelic S, Lederer DJ, Adams T, et al. Vascular inflammation in obesity and sleep apnea. Circulation. 2010; 121: 1014-21.
33. Philipps BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in leptin levels, sympathetic drive and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol. 2000; 279: H234-7.
34. Barceló A, Barbé F, Llompart E, et al. Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. Am J Respir Crit Care Med. 2005; 171: 183-7.
35. Coughlin SR, Mawdyley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J. 2004; 25: 735-41.
36. McArdle N, Hillman D, Beilin L, Watts G. Metabolic risk factors for vascular disease in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med. 2007; 175: 190-5.
37. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med. 2002; 165: 670-6.
38. Elmasry A, Lindberg E, Berne C, et al. Sleep-disordered breathing and glucose metabolism in hypertensive men: a population-based study. J Intern Med. 2001; 249: 153-61.
39. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med. 2007; 175: 851-7.
40. Savransky V, Nanayakkara A, Li J, et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med. 2007; 175: 1290-2197.
41. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2005; 172: 613-8.
42. Sorajja D, Gami AS, Somers VK, Behrenbeck TR, Garcia-Touchard A, Lopez-Jimenez F. Independent association between obstructive sleep apnea and subclinical coronary artery disease. Chest. 2008; 133: 927-33.
43. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am Respir Crit Care Med. 2007; 176: 706-12.
44. Wattanakit K, Boland L, Punjabi NM, Shabar E. Relation of sleep-disordered breathing to carotid plaque and intima-media thickness. Atherosclerosis. 2008; 197: 125-31.
45. Schäfer H, Koehler U, Ewig S, Hasper E, Tasci S, Lüderitz B. Obstructive sleep apnea as risk factor in coronary artery disease. Cardiology. 1999; 92: 79-84.
46. Mooe T, Franklin KA, Holmström K, Rabben T, Wiklund U. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med. 2001; 164: 1910-3.
47. Shahar E, Whitney DW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease. Cross sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001; 163: 19-25.
48. Marin JM, Carrizo SJ, Vicente E, Augusti AGN. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005; 365: 1046-53.
49. Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing and the occurrence of stroke. J Respir Crit Care Med. 2005; 172: 1447-51.
50. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005; 353: 2034-41.
51. Yumino D, Tsurumi Y, Takagi A, Suzuki K, Kasanuki H. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J Cardiol. 2007; 99: 26-30.
52. Valham F, Mooe T, Rabben T, Stenlund H, Wiklund U, Franklin KA. Increased risk of stroke in patients with coronary artery disease and sleep apnea: a 10-year follow-up. Circulation. 2008; 118: 995-60.
53. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010; 122: 352-60.
54. Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effect of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest. 2005; 127: 2076-84.
55. Milleron O, Pilliere R, Foucher A, et al. Benefits of obstructive sleep apneas treatment in coronary artery disease: a long-term follow-up study. Eur Heart J. 2004; 25: 728-34.
56. Martinez-Garzia MA, Galiano-Blancart R, Roman-Sanchez P, et al. Continuous positive airway pressure treatment in sleep apnea prevents new vascular events after ischemic stroke. Chest. 2005; 128: 2123-9.
57. Buchner NJ, Sanner BM, Borgel J, Rump LC. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med. 2007; 176: 1274-80.
58. Cassar A, Morgenthaler TI, Lennon RJ, Rihal CS, Lerman A. Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention. J Am Coll Cardiol. 2008; 50: 1310-4.
59. Peled N, Abinader EG, Pillar G, Sharif D, Lavie P. Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment. J Am Coll Cardiol. 1999; 34: 1744-9.
60. Konecny T, Kuniyoshi FH, Orban M, et al. Under-diagnosis of sleep apnea in patients after acute myocardial infarction. J Am Coll Cardiol. 2010; 56: 742-3.
61. Parra O, Arboix A, Bechich S, et al. Time course of sleep-related breathing disorders in first-ever stroke or transient ischemic attack. Am J Respir Crit Care Med. 2000; 161: 375-80.
62. Franklin KA. Cerebral haemodynamics in obstructive sleep apnea and Cheyne-Stokes respiration. Sleep Med Rev. 2002; 6: 429-41.
63. Minoguchi K, Yokoe T, Tazaki T, et al. Silent brain infarction and platelet activation in obstructive sleep apnea. Am J Respir Crit Care Med. 2007; 1(7): 612-7.
64. Hu FB, Willett WC, Manson JE, et al. Snoring and risk of cardiovascular disease in women. J Am Coll Cardiol. 2000; 35: 308-13.
65. Kohler M, Craig S, Nicoll D, Leeson P, Davies RJ, Stradling JR. Endothelial function and arterial stiffness in minimally symptomatic obstructive sleep apnea. Am J Respir Crit Care Med. 2008; 178: 984-8.
66. Turmel J, Sériès F, Boulet LP, et al. Relationship between atherosclerosis and the sleep apnea syndrome: an intravascular ultrasound study. Int J Cardiol. 2009; 132: 203-9.
67. Lefebvre B, Pépin JL, Baguet JP, et al. Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? Eur Respir J. 2008; 32: 113-20.
68. Ryan S, Taylor CT, McNicholas WT. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Postgrad Med J. 2009; 85: 693-8.
69. Lavie L, Polotsky V. Cardiovascular aspects in obstructive sleep apnea syndrome - Molecular issues, hypoxia and cytokine profiles. Respiration. 2009; 78: 361-70.
70. Kheirandish-Gozal L, Capdevila OS, Tauman R, Gozal D. Plasma C-reactive protein in nonobese children with obstructive sleep apnea before and after adenotonsillectomy. J Clin Sleep Med. 2006; 2: 301-4.
71. Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med. 2005; 172: 625-30.
72. Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest. 2004; 126: 1473-9.
73. Ohga E, Nagase T, Tomita T, et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol. 1999; 87: 10-4.
74. El-Solh AA, Mador MJ, Sikka P, Dhillon RS, Amsterdam D, Grant BJ. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest. 2002; 121: 1541-7.
75. Nácher M, Serrano-Mollar A, Farré R, Panés J, Seguí J, Montserrat JM. Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir Physiol Neurobiol. 2007; 155: 93-6.
76. Kobayashi K, Nishimura Y, Shimada T, et al. Effect of continuous positive airway pressure on soluble CD40 ligand in patients with obstructive sleep apnea syndrome. Chest. 2006; 129: 632-7.
77. Polotsky VY, Savransky V, Bevans-Fonti S, et al. Intermittent and sustained hypoxia induce a similar gene expression in the human aortic endothelial cells. Physiol Genomics. 2010. doi: 10. 1152/physiolgenomics. 00091. 2009.
78. Quercioli A, Mach F, Montecucco F. Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath. 2010; 14: 261-9.
79. Arnaud C, Dematteis M, Pepin JL, Baguet JP, Lévy P. Obstructive sleep apnea, immuno-inflammation, and atherosclerosis. Semin Immunopathol. 2009; 31: 113-25.
80. Gozal D, Serpero LD, Sans Capdevila O, Kheirandish-Gozal L. Systemic inflammation in non-obese children with obstructive sleep apnea. Sleep Med. 2008; 9: 254-9.
81. Dyugovskaya L, Lavie P, Lavie L. Phenotypic and functional characterization of blood gammadelta T cells in sleep apnea. Am J Respir Crit Care Med. 2003; 168: 242-9.
82. Iesato K, Tatsumi K, Saibara T, et al. Decreased lipoprotein lipase in obstructive sleep apnea syndrome. Circ J. 2007; 71: 1293-8.
83. Lam JC, Ip MS. Obstructive sleep apnea and the metabolic syndrome. Expert Rev Respir Med. 2009; 3: 177-86.
84. Tkacova R, Rizzo M, Berneis K. Therapy with noninvasive ventilation in patients with obstructive sleep apnoea: effects on atherogenic lipoprotein phenotype. Med Hypotheses. 2009; 73: 441-4.
85. Adeseun GA, Rosas SE. The impact of obstructive sleep apnea on chronic kidney disease. Curr Hypertens Rep. 2010; 12: 378-83.
86. Lavie L. Obstructive sleep apnoea syndrome- an oxidative stress disorder. Sleep Med Rev. 2003; 7: 35-51.
87. Barceló A, de la Peña M, Ayllón O, et al. Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in patients with sleep apnea. Respiration. 2009; 77: 85-90.
88. Belaidi E, Joyeux-Faure M, Ribuot C, Launois SH, Levy P, Godin-Ribuot D. Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol. 2009; 53: 1309-17.
89. Kim J, Bhattacharjee R, Snow AB, Capdevila OS, Kheirandish-Gozal L, Gozal D. Myeloid-related protein 8/14 levels in children with obstructive sleep apnoea. Eur Respir J. 2010; 35: 843-50.
90. Dyugovskaya L, Polyakov A, Lavie P, Lavie L. Delayed neutrophil apoptosis in patients with sleep apnea. Am J Respir Crit Care Med. 2008; 177: 544-54.
91. Tamaki S, Yamauchi M, Fukuoka A, et al. Nocturnal hypoxic stress activates invasive ability of monocytes in patients with obstructive sleep apnoea syndrome. Respirology. 2009; 14: 689-94.
92. Lattimore JD, Wilcox I, Nakhla S, Langenfeld M, Jessup W, Celermajer DS. Repetitive hypoxia increases lipid loading in human macrophages-a potentially atherogenic effect. Atherosclerosis. 2005; 179: 255-9.
93. Dyugovskaya L, Lavie P, Lavie L. Lymphocyte activation as a possible measure of atherosclerotic risk in patients with sleep apnea. Ann NY Acad Sci. 2005; 1051: 340-50.
94. El Solh AA, Akinnusi ME, Baddoura FH, Mankowski CR. Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med. 2007; 175: 1186-91.
95. El Solh AA, Akinnusi ME, Berim IG, Peter AM, Paasch LL, Szarpa KR. Hemostatic implications of endothelial cell apoptosis in obstructive sleep apnea. Sleep Breath. 2008; 12: 331-7.
96. Ayers L, Ferry B, Craig S, Nicoll D, Stradling JR, Kohler M. Circulating cell-derived microparticles in patients with minimally symptomatic obstructive sleep apnoea. Eur Respir J. 2009; 33: 574-80.
97. Jelic S, Lederer DJ, Adams T, et al. Endothelial repair capacity and apoptosis are inversely related in obstructive sleep apnea. Vasc Health Risk Manag. 2009; 5: 909-20.
98. Barceló A, Piérola J, López-Escribano H, et al. Telomere shortening in sleep apnea syndrome. Respir Med. 2010; 104: 1225-9.
99. Karkoulias K, Lykouras D, Sampsonas F, et al. The role of Endothelin-1 in obstructive sleep apnea syndrome and pulmonary arterial hypertension: pathogenesis and Endothelin-1 antagonists. Curr Med Chem. 2010; 17: 1059-66.
100. Antonescu-Turcu A, Parthasarathy S. CPAP and Bi-level PAP therapy: new and established roles. Respir Care. 2010; 55: 1216-29.
101. Vanderveken OM, Boudewyns A, Ni Q, et al. Cardiovascular implications in the treatment of obstructive sleep apnea. J Cardiovasc Transl Res. 2011; 4: 53-60.
102. Grebe M, Eisele HJ, Weissmann N, et al. Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med. 2006; 173: 897-901.
103. Li J, Nanayakkara A, Jun J, Savransky V, Polotsky VY. Effect of deficiency in SREBP cleavage-activating protein on lipid metabolism during intermittent hypoxia. Physiol Genomics. 2007; 31: 273-80.